EBITDA cure: Struggling firms inject cash to avoid a collapse
This year has seen only a handful of major distress opportunities in the private equity space, but concerns are mounting that a number of groups are shifting their problems down the line.
This year has seen only a handful of major distress opportunities in the private equity space, but concerns are mounting that a number of groups are shifting their problems down the line.
The move to shore up its defences no doubt has been brought on by fears of an opportunistic buyout offer.
Embattled private hospital operator Healthscope is understood to have embarked on the sale and leaseback of its hospital equipment in an effort to get money through the door.
Now that Genesis Capital appears to have gained control of Pacific Smiles, the sale process for rival dental care chain Ekera Dental, owned by the Growth Fund, could reignite.
The next chapter for Peabody Energy following its acquisition of Anglo American’s coal mines for up to $5.8bn will be funding the assets.
The sale of the business is likely to conclude next month.
Ramelius Resources’ move on smaller rival Spartan could be contingent on the release soon of its feasibility study into its Rebecca-Roe development.
The passing of the federal government’s aged-care bill is expected to trigger a fresh round of merger and acquisition activity in the sector.
Fonterra’s request for a court ruling on the rights Bega Cheese has in its licensing agreement is understood to have been triggered by prospective buyers wanting clarity ahead of its asset sale.
The demand for initial public offerings from retail investors, highlighted by the latest HMC Capital float, has thrown the spotlight back on the $4bn pet care group Greencross.
Original URL: https://www.theaustralian.com.au/author/bridget-carter/page/8